Validation of the Bleeding Academic Research Consortium

Reference: Circulation. 2012; 125:1424–143

Abstract: For many years all efforts applied to the optimization of percutaneous coronary intervention (PCI) were aimed specifically at reducing ischemic events risk through the advent of: 1) new devices (medicated stents), reducing restenosis rates, revascularization and 2) development of new drugs with a potent anti-platelet or anticoagulant such as clopidogrel or, more recently, prasugrel, ticagrelor, 2b3a inhibitors and direct thrombin inhibitors (DTIs) like bivalirudin among others. However, we have identified that in the mortality equation after PCI, ischemic risk plays an important role. Certainly, the risk of bleeding complications or bleeding itself has been recognized as dominant variables that directly influence the mortality rates of patients who have undergone PCI. Nevertheless, bleeding classification and definition has been very heterogeneous (TIMI, GUSTO, CURE, ACUITY, CURRENT OASIS, STEEPLE, GRACE, REPLACE 2)1, which has negative influences in accurately quantifying its incidence, severity and consequences (mortality). In this regard, the Bleeding Academic Research Consortium (BARC) 1 was recently formed, based on the idea of

More articles by this author

Download the Official SOLACI-CACI 2024 Congress APP

  DOWNLOAD THE OFFICIAL APP OF SOLACI-CACI 2024 Next Wednesday marks the beginning of SOLACI-CACI 2024! Download the Congress APP and discover the unmissable program of the...

Survey on Hemodynamics Centers in Latin America – SOLACI, Stent Save a Life! and South American Society of Cardiology Initiative

The treatment of ST-segment elevation myocardial infarction (STEMI) in Latin America is highly diverse. There are notable differences between countries and even among regions...

SOLACI-SBHCI 2023 Congress Has Begun!

Let the best begin! After a year of intense work, SOLACI-SBHCI 2023 Congress—the widest, most important event for interventional cardiologists in Latin America—has kicked...

SOLACI-SBHCI 2023 Congress Has Begun!

Let the best begin! After a year of intense work, SOLACI-SBHCI 2023 Congress—the widest, most important event for interventional cardiologists in Latin America—has kicked...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...